ACRO is led by a distinguished team of industry, drug development, and technology experts that comprise ACRO’s Board of Directors. Our Board of Directors is dedicated to advocating on behalf of safe, efficient, and effective clinical trials that protect patients and ensure high-quality results.

All Regular ACRO members maintain a seat on our Board of Directors. In addition, our Board’s Executive Committee is comprised of the current ACRO Chair, Vice-Chair, and immediate Past-Chair.

Board of Directors

Jim Corrigan

CEO, YPrime

Catherine Gregor

Chief Clinical Trial Officer, Florence Healthcare

Peyton Howell

Chief Executive Officer, Parexel
ACRO Chair

Karen Kaucic

President, Patient and Advisory Services & Chief Medical Officer, Clinical Research, PPD, Part of Thermo Fisher Scientific

Sandy Kennedy

Chief Quality, Regulatory Affairs, & Sustainability Officer, Fortrea

Greg Licholai

Chief Medical & Innovation Officer, ICON plc

Lisa Moneymaker

Chief Technology Officer & Chief Product Officer, Saama

Jim Reilly

Vice President, Vault R&D, Veeva

Gadi Saarony

CEO, Advarra

Joseph Schmidt

EVP, Head of Customer Services and Success, Medidata

Seema Verma

SVP & GM, Oracle Life Sciences

Cynthia Verst

President, Design & Delivery Innovation, Research & Development Solutions, IQVIA

ACRO Staff

Anina Adelfio

Chief Operating Officer

Sophia McLeod

Sr. Director, Government Relations

Karen Noonan

Senior Vice President, Global Regulatory Policy

Doug Peddicord

Executive Director

Aislinn Quinn

Communications Director

Daniela Shia-Sevilla

Membership Associate

Scroll to Top